Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical and biological significance of RAS mutations in multiple myeloma

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM . Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571–596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    Article  CAS  PubMed  Google Scholar 

  3. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999; 35: 83–89.

    Article  CAS  PubMed  Google Scholar 

  4. Oken MM, Leong T, Lenhard Jr RE, Greipp PR, Kay NE, Van Ness B et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999; 86: 957–968.

    Article  CAS  PubMed  Google Scholar 

  5. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM . Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323.

    Article  CAS  PubMed  Google Scholar 

  6. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212–224.

    Article  CAS  PubMed  Google Scholar 

  7. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD . Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001; 98: 1555–1560.

    Article  CAS  PubMed  Google Scholar 

  8. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582–584.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R Fonseca.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chng, W., Gonzalez-Paz, N., Price-Troska, T. et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 22, 2280–2284 (2008). https://doi.org/10.1038/leu.2008.142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.142

This article is cited by

Search

Quick links